CMBC International: AI Empowers the "Medicine-Insurance-Patient" Ecosystem YIDU TECH (02158) Sees a Turning Point in Performance

ZhaoYin International released a research report stating that YIDU TECH (02158) is a leading medical AI company in China, with its core algorithm YiduCore deployed in several top domestic hospitals. Based on YiduCore, the company has built three main business segments targeting hospitals, pharmaceutical companies, and patients, with rapid growth in orders in the first half of the 26th fiscal year. YIDU TECH is expected to achieve its first annual profit in the 26th fiscal year, and the high-frequency, large-scale repurchases in 2026 demonstrate the management's confidence in the company. ZhaoYin International's main points include: Leading AI medical technology platform in China YIDU TECH's AI capabilities have formed a complete closed loop of "data-algorithm-scenario-commercialization". YiduCore is the core algorithm engine of YIDU TECH's entire AI capability system and the company's medical AI brain. YiduCore has accumulated processing more than 7 billion authorized real-world medical data, allowing it to understand diseases much deeper than generic models trained on public corpora. YIDU TECH has built a platform-level intelligent base through AI middle platform, using the "1+N+X" Copilot product matrix design, where 1 AI middle platform serves as a unified base, integrating N large models to empower X business scenarios. YIDU TECH's AI technology is continuously being implemented. In March 2026, the company officially launched YiduZhiXun aimed at doctors, a smart clinical evidence-based system, which has been deployed in 50 top hospitals nationwide. In clinical practice, the company's large model has increased the accuracy of TNM staging analysis at Sun Yat-sen University Cancer Hospital from 58% to 90%, reaching the diagnostic level of chief physicians. In addition, AI has increased patient recruitment efficiency by 3-5 times and reduced screening costs by 88%. AI empowers three major business platforms YIDU TECH's three major business segments revolve around the "medical-pharmaceutical-insurance-patient" ecosystem, creating big data platforms and solutions (AI for Medical), life science solutions (AI for Life Science), and health management platforms and solutions (AI for Care). AI for Medical empowers clinical diagnosis, scientific research, and hospital management across hospitals and regulatory agencies. The cooperation between the company and Sun Yat-sen University Cancer Hospital is a model of AI empowerment in China's medical field. AI for Life Science targets pharmaceutical companies, covering clinical trials, real-world research, drug commercialization, and has served 17 out of the top 20 multinational pharmaceutical companies in the first half of the 26th fiscal year. AI for Care targets consumers and governments, operating programs like medical insurance and digital therapy. The three major business segments share the underlying YiduCore intelligent engine, where high-quality clinical data accumulated at the hospital end feeds back into drug research and real-world research at the pharmaceutical end, while also empowering risk prediction and health management at the insurance end. As of September 2025, the new signed orders for the AI for Medical segment increased by 19.7% year-on-year, with orders on hand exceeding 400 million RMB; the new signed orders for the AI for Life Science segment increased significantly by 61.1% year-on-year, with orders on hand nearly reaching 400 million RMB. Diversified AI expansion strategy On June 1, 2026, YIDU TECH announced its intention to acquire 100% equity of an online doctor platform for approximately 400 million RMB. As of March 2026, the platform had accumulated around 3.5 million practicing doctor users. Leveraging its leading AI technology capabilities, YIDU TECH will combine the acquired company's extensive doctor network and mature medical service channels to promote the scaled landing of AI technology and products. The Southeast Asian market has become the frontline for the company's overseas business expansion. The company's overseas revenue mainly comes from Brunei, where it has built the national health platform BruHealth covering 90% of the population. The revenue in the first half of the 26th fiscal year has reached 13%. In addition to Southeast Asia, the company is also exploring international markets in the United States and the Middle East. Performance growth and shareholder return resonant On April 20, 2026, YIDU TECH released a positive profit forecast, expecting the net profit attributable to shareholders in the fiscal year 2026 ending on March 31, 2026 to reach 41 to 56 million RMB, marking the company's first annual profit since its listing. This is mainly driven by the growth in orders, revenue growth, and continuous improvement in profit margin and expense ratio. At the same time, YIDU TECH's stock repurchases have been increasing in intensity and frequency year by year. In particular, in February and March 2026, the company repurchased 58 million RMB and 146 million Hong Kong dollars respectively, accounting for 82.4% of the total repurchase amount for the 26th fiscal year. These high-frequency, large-scale repurchases demonstrate the management's confidence in the company's intrinsic value.